OverviewChartProfileKey statisticsFinancialsNews
Derivatives
TraderScreen

LILLY ELI/  US5324571083  /

SIX Swiss Exchange
2024-07-26  10:10:00 PM Chg. 0.00 Volume Bid2024-07-26 Ask2024-07-26 Market Capitalization Dividend Y. P/E Ratio
775.00CHF 0.00% -
Turnover: -		 -Bid Size: 0 -Ask Size: 0 675.8 bill.CHF - -
TeleTrader 07-08 Eli Lilly launches $3.2B tender offer for Morphic
TeleTrader 07-02 US FDA approves Eli Lilly's Alzheimer's drug
TeleTrader 06-25 Lilly partners with OpenAI to combat drug-resistance bacteria
TeleTrader 06-10 FDA advisors endorse Eli Lilly's Alzheimer's drug
TeleTrader 05-24 Eli Lilly to reveal $5.3B production boost
TeleTrader 05-21 Eli Lilly's diabetes drug receives authorization in China
TeleTrader 04-30 Eli Lilly's Q1 revenue surges 26% to $8.8B
TeleTrader 03-08 Lilly's Alzheimer's drug delayed beyond Q1 2024 by FDA
GlobeNewswire 02-28 HUTCHMED Reports 2023 Full Year Results and Provides Business Updates
TeleTrader 02-26 Zealand Pharma soars 30% on positive weight-loss drug results
TeleTrader 02-06 Eli Lilly surges 5% premarket on better-than-expected results
TeleTrader 02-06 Eli Lilly revenue in Q4 up 28% to $9.35B
TeleTrader 01-04 Eli Lilly unveils website to improve weight-loss drug access
TeleTrader 2023-10-03 Eli Lilly to buy Point Biopharma for $1.4 billion
TeleTrader 2023-08-08 Eli Lilly soars 14% after upbeat earnings
TeleTrader 2023-08-08 Eli Lilly jumps 10% in premarket after earnings
TeleTrader 2023-08-08 Eli Lilly's revenue in Q2 surges 28% to $8.3B
TeleTrader 2023-06-20 Eli Lilly to acquire Dice Therapeutics for $2.4B
TeleTrader 2023-05-03 Eli Lilly soars 5% after positive Alzheimer's trial
TeleTrader 2023-04-27 Eli Lilly's Q1 net income sinks 29% to $1.35 billion
TeleTrader 2023-04-21 Drug firms CEOs to testify on insulin prices in Senate
TeleTrader 2023-03-08 Eli Lilly Alzheimer's drug fails prevention study
TeleTrader 2023-03-01 Eli Lilly caps, cuts insulin prices by 70%
TeleTrader 2023-02-02 Eli Lilly's Q4 EPS up by 13% to $2.14 per share
TeleTrader 2022-12-13 Eli Lilly's 2023 adjusted profit guidance comes below estimates